Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CERS 
Cerus Corporation (CERS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/17/2025: CERS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.67
1 Year Target Price $4.67
| 4 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.91% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 311.18M USD | Price to earnings Ratio - | 1Y Target Price 4.67 |
Price to earnings Ratio - | 1Y Target Price 4.67 | ||
Volume (30-day avg) 5 | Beta 1.57 | 52 Weeks Range 1.12 - 2.23 | Updated Date 11/17/2025 |
52 Weeks Range 1.12 - 2.23 | Updated Date 11/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When - | Estimate -0.0267 | Actual -0.0001 |
Profitability
Profit Margin -8.01% | Operating Margin (TTM) 2.35% |
Management Effectiveness
Return on Assets (TTM) -2.93% | Return on Equity (TTM) -27.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 330855751 | Price to Sales(TTM) 1.56 |
Enterprise Value 330855751 | Price to Sales(TTM) 1.56 | ||
Enterprise Value to Revenue 1.66 | Enterprise Value to EBITDA -13.19 | Shares Outstanding 192087501 | Shares Floating 173491510 |
Shares Outstanding 192087501 | Shares Floating 173491510 | ||
Percent Insiders 3.34 | Percent Institutions 71.68 |
Upturn AI SWOT
Cerus Corporation
Company Overview
History and Background
Cerus Corporation was founded in 1991 and focuses on developing and commercializing the INTERCEPT Blood System. The company has evolved from research to a commercial stage company focusing on blood safety.
Core Business Areas
- Blood Safety: Developing and commercializing the INTERCEPT Blood System to inactivate pathogens in blood components intended for transfusion. INTERCEPT inactivates viruses, bacteria, parasites and leukocytes, reducing the risk of transfusion-transmitted infections.
Leadership and Structure
William 'Obi' Greenman is the President and CEO. The organizational structure is typical of a publicly traded biotech company with functional departments like R&D, Commercial Operations, and Finance.
Top Products and Market Share
Key Offerings
- INTERCEPT Blood System for Plasma: A system used to inactivate pathogens in plasma before transfusion. Competitors include Macopharma and Terumo BCT.
- INTERCEPT Blood System for Platelets: A system used to inactivate pathogens in platelet concentrates before transfusion. Cerus's market share of the pathogen reduction system (PRS) market for platelets is substantial in regions where it is implemented. Key competitor is Macopharma with its Mirasol system
- INTERCEPT Blood System for Red Blood Cells: Under development to inactivate pathogens in red blood cells. No significant competitor commercially available yet.
Market Dynamics
Industry Overview
The blood safety industry is driven by the need to reduce transfusion-transmitted infections and improve blood availability. Increasing regulatory scrutiny and emerging pathogens are key drivers.
Positioning
Cerus is a leader in pathogen reduction technology for blood safety. Its competitive advantage lies in its broad spectrum pathogen inactivation capabilities and regulatory approvals in key markets.
Total Addressable Market (TAM)
The estimated TAM for pathogen reduction technology in blood is in the billions of dollars. Cerus is well-positioned to capture a significant portion of this TAM, particularly as pathogen reduction becomes a standard of care in more regions.
Upturn SWOT Analysis
Strengths
- Established technology with regulatory approvals
- Strong intellectual property portfolio
- Experienced management team
- Leader in pathogen reduction for platelets and plasma
Weaknesses
- Reliance on a limited number of products
- High operating expenses
- Dependence on regulatory approvals and reimbursement
- Slow adoption in some markets
Opportunities
- Expanding into new geographic markets
- Developing new applications for INTERCEPT technology
- Partnering with blood centers and hospitals
- Expanding use into red blood cell transfusions
Threats
- Competition from alternative technologies
- Changes in regulatory requirements
- Economic downturn affecting healthcare spending
- Emergence of new pathogens requiring alternative solutions
Competitors and Market Share
Key Competitors
- MTOX
- TERU
Competitive Landscape
Cerus has a strong position in platelet and plasma pathogen reduction. Competitors like Macopharma and Terumo BCT offer alternative technologies. Cerus's broad spectrum inactivation is a key advantage.
Growth Trajectory and Initiatives
Historical Growth: Cerus has experienced steady revenue growth as the INTERCEPT Blood System gains wider adoption.
Future Projections: Analysts project continued revenue growth as Cerus expands into new markets and receives regulatory approvals for new applications. Expected to see substantial revenue increase once adopted for Red Blood Cell Transfusions.
Recent Initiatives: Expanding into new geographic markets, pursuing regulatory approval for red blood cells, and collaborating with blood centers to increase adoption of INTERCEPT.
Summary
Cerus Corporation is a key player in the blood safety market, leading the way with its INTERCEPT Blood System. Strong technology and regulatory approvals position the company well for continued growth. High operating expenses and slow market adoption remain key challenges. The future outlook is positive, with opportunities to expand geographically and into new applications, especially red blood cells.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Cerus Corporation Investor Relations, SEC Filings, Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cerus Corporation
Exchange NASDAQ | Headquaters Concord, CA, United States | ||
IPO Launch date 1997-01-30 | President, CEO & Chairman Mr. William M. Greenman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 614 | Website https://www.cerus.com |
Full time employees 614 | Website https://www.cerus.com | ||
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.